Substantial increases in idarubicin plasma concentration by liposome encapsulation mediates improved antitumor activity

This publication has 33 references indexed in Scilit:

• Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells
  Biochemical Pharmacology, 2002
• Idarubicin overcomes P-glycoprotein-related multidrug resistance: comparison with doxorubicin and daunorubicin in human multiple myeloma cell lines
  Leukemia Research, 1999
• Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma.
  Journal of Clinical Oncology, 1996
• Doxorubicin Encapsulated in Liposomes Containing Surface‐Bound Polyethylene Glycol: Pharmacokinetics, Tumor Localization, and Safety in Patients with AIDS‐Related Kaposi's Sarcoma
  The Journal of Clinical Pharmacology, 1996
• Susceptibility of idarubicin, daunorubicin, and their C-13 alcohol metabolites to transport-mediated multidrug resistance
  Biochemical Pharmacology, 1995
• Evaluation of resistance index of several anticancer agents on parental and resistant P-388 cell lines
  Leukemia Research, 1995
• Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells
  Blood, 1992
• Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia
  Blood, 1992
• Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia
  Blood, 1991
• Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells
  Cancer Chemotherapy and Pharmacology, 1990